# IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors

> **NCT03665129** · PHASE1 · TERMINATED · sponsor: **Innate Pharma** · enrollment: 73 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **BIOLOGICAL:** IPH5401 and Durvalumab

## Key facts

- **NCT ID:** NCT03665129
- **Lead sponsor:** Innate Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-09-07
- **Primary completion:** 2021-02-24
- **Final completion:** 2021-02-24
- **Target enrollment:** 73 (ACTUAL)
- **Why stopped:** early termination
- **Last updated:** 2022-01-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03665129

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03665129, "IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03665129. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*